Given that Boryung won a series of previous referees, the pharmaceutical industry is paying keen attention to the decision, which is the opposite of the previous one.

◆Patent judge decides opposite to previous judgment

According to the pharmaceutical industry on the 2nd, the Korean Intellectual Property Tribunal made a claim citation decision on the 31st of last month in a passive judgment on the scope of rights for patent of Dukarb filed by Huons against Boryung.

For generic companies, including Huons, they won the Dukarb patent dispute for the first time. The Dukarb patent dispute began in March last year when 40 pharmaceutical companies filed a series of